GlaxoSmithKline has received FDA approval for Tanzeum (albiglutide) subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with Type 2 diabetes.

Tanzeum is a glucagon-like peptide-1 (GLP-1) receptor agonist, a hormone that helps normalize blood sugar levels. The drug's safety and effectiveness were evaluated in eight clinical trials involving more than 2,000 patients with Type 2 diabetes. Patients participating in the trials showed an improvement in their HbA1c level (hemoglobin A1c or glycosylated hemoglobin, a measure of blood sugar control.

Source: FDA